Domain Therapeutics Strengthens Its Intellectual Property for Its Series of Treg Depleting anti-CCR8 Antibodies, Including Best-in-class Candidate DT-7012
2024-06-06
免疫疗法
Recent publication of three international Patent Cooperation Treaty (PCT) patent applications covering Domain’s series of Treg depleting anti-CCR8 antibodies.
Three new patents expand geographic protection of the Company’s best-in-class CCR8 asset.
Depletion of T regulatory cells via CCR8, a GPCR target specific to these cell types in the tumor microenvironment, is a highly strategic approach in immuno-oncology to improve clinical outcomes in cancer patients.
STRASBOURG, France & MONTREAL & BOSTON--(BUSINESS WIRE)-- Domain Therapeutics (“Domain” or “the Company”), a global clinical-stage biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptor (GPCR) driven immuno-resistance, today announces the publication of three international PCT patent applications.
These patents will significantly strengthen the Company’s intellectual property protection for its series of tumor-infiltrating regulatory T cells (Tregs) depleting antibody-dependent cell-mediated cytotoxicity/ phagocytosis (ADCC/ADCP) anti-CCR8 antibodies, including DT-7012, a novel drug candidate with best-in-class potential compared to other clinical-stage CCR8 antibodies. Currently in the pre-IND stage of development, DT-7012 is set to commence Phase I clinical trials in early 2025.
Stephan Schann, Chief Scientific Officer of Domain Therapeutics, said: “These three new patents are pivotal to our strategy, enhancing our robust patent estate and expanding our reach across diverse market opportunities. They underscore the broad international application of our Treg depleting ADCC/ADCP anti-CCR8 antibodies, particularly for our lead anti-CCR8 candidate DT-7012. They also reinforce Domain’s position as an industry leader in GPCR-mediated immunotherapies. Notably, this timely publication of PCT patent applications aligns with our accelerated and broadened research and development efforts in immuno-oncology.”
CCR8 is a GPCR target specifically expressed by tumor infiltrating Tregs, major immunosuppressive cells responsible for the failure of several therapeutics in the clinic, which makes this target highly strategic for the development of efficient novel immunotherapies.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。